Immunomodulation During Pregnancy Through Low-Dose Aspirin: a Hypothetical Mechanism for the Prevention of Preeclampsia?

What this Trial Is About

This research aims to understand how low dose aspirin (LDA) affects immune cells during pregnancy, focusing on women at high risk for preeclampsia (PE). The study evaluates the impact of LDA on both innate immunity cells like NK cells and monocytes, and acquired immunity cells such as B and T lymphocytes. It also compares immune responses and pregnancy outcomes between women at high risk who receive aspirin and those at low risk who do not. The study is observational and includes 30 pregnant women monitored over at least 40 weeks, up to 24 months. Participants are grouped into high risk for PE, who receive daily 150 mg aspirin starting before 14 weeks gestation, and low risk who do not take aspirin. Blood samples will be taken during each trimester to analyze immune cell changes and cytokine levels. Additional samples are collected before and after aspirin use in the high-risk group. After delivery, placental tissue and umbilical cord blood will be examined for immune markers. Participants will attend prenatal consultations where blood tests are performed alongside routine care. Researchers will use advanced lab methods to measure immune cells and cytokines. Outcomes include immune cell modulation at 30 weeks and maternal health measures. The study also examines placental tissue after birth. This trial is led by Unidade Local de Saúde de Coimbra, EPE, and participation involves regular pregnancy monitoring with added blood collections and assessments.

Immunomodulation During Pregnancy